Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So leave. Easy :)
Oh made good profit in May-June 2015 run.
You didn't? Such a shame!
Well not very smart investment strategy when never exiting to take profit. Comes with any biotech.
Welcome to biotech!
Have the courage of your conviction and in your DD
Phase 2 trials are running. What can one reasonaly expect more? There is no fast-forward button to get results earlier!
Interim results are promised this year and they are a stated evaluation moment before going from 50% enrollment to 100%
First will be the combo-trial results with Durvalumab at Sloan Kettering.
So you were able to contact the major shareholders and convince them to dump Wilson? I guess some shareholders also told you coincidently that they will dump shares shoon?
I whish I was able to speek with our major shareholders!
As for Durvamulab, go back a couple of postings and one will find a nice summary by RKmatters regarding Durvamulab and TIL. As you are well aware that is exactly what our drug does: increasing TIL-levels.
We are not at risk of losing anything. Don't scare monger.
12 mil DOD dollars will fund a phase 2 trial at Mayo.
So get in contact with Mayo and tell them. I am sure they must be unaware of this.
contact Mayo and ask them.
Your basic assumption they would PR the submission of and IND. Why?
Suggest you do your own calls and emails. Good luck
Uh-huh
Oh now it's a consultant...
I believe we all share the same goal: advance the science and make some money.
Personally I do not share the analysis that Dr Wilson is the key problem. Trials are running, partnering with great institutions like Mayo and Sloan Kettering, funding by DOD, collaboration with AstraZeneca,...
In the absence of news the stock price goes down. I am happy with my DD to know that the fundamentals are good and all we need is time for the phase 2 trials to work out. Should start hearing more on interim results towards the end of the year
Please do not put words in my mouth. Not hanging on to anything or anyone.
That is not advocating but going off on a rant.
The choice of communication channel for this change is rather an ineffective one. I do not believe that the major shareholders of TapImmune are basing their decisions on postings made on an anonymous board.
So channel all this frustration into contacting the major shareholders and convince them they are making the wrong choice by continuing to support this CEO.
Good luck.
Seriously, I see no ghosts.
I have not been informed about 10 people, I have always heard and read about 20 in phase 1.
As for Glynn, I do not need to be his best bud.
Am I disappointed about the current share price? Sure. Am I surprise? No. We are in an information lull with multiple phase 2 trials starting or getting started. What we need know is time and patience for those trials to run their course.
The results from these trials will be the make or break of this company.
Have the patience and courage of one's investment or move on.
What growing uncertainty? Phase 2 trials are running, let time do its work.
Only fearmongering
Same song everyday: CEO needs go, CEO needs to go..... wash, rinse, repeat....
I suggest to contact that communication consult and ask your question. I prefer to base my decisions on SEC declarations and clinicaltrials.gov data.
The only number that matters is the one on clinical trials. Link to the communication with 10 patients?
Seriously, get a grip
Wanna know the trial participants? Check out the clinical trial pages.
Why would we bother chasing Wilson to facilitate an obsession with removal?
Likely but not before we have p2 data, so a while out
Go check the clinical trial pages or google cache
Reply by RKMatter regarding AZN-Merck news and Durvalumab. All credits to her.
Yes, I've seen it. It is down likely due to Durvalumab not performing as the blockbuster that they thought it might. This Mystic news:
http://www.biospace.com/News/astrazeneca-plc-loses-10-billion-in-value-as-long/464250
They are not giving up on durvalumab. They intend to also combine it with their PARP inhibitor. But, it is a very smart move for them to test their PARP inhibitor in combination with competing PD1s and PDL1s.
One thing that should be understood is that with cancer the checkpoint inhibitors only work well in tumors that express pre-existing TIL. And so it shouldn't be a shock that the mystic trial failed even when in combination with tremelimumab, a CTLA-4 inhibitor. Neither can change the amount of TIL found within a tumor. They can only unblock the T cell response on the pre-existing levels. The mystic trial combination therapy was still left to work with the level of TIL that was there. They were dependent on a preexisting TIL population
Now having said that, the dendritic cells and the T cell therapies, like TPIV's, have the capacity to improve pre-existing TIL levels. They just run into issues with T cell exhaustion when PDL1 levels start rising. Basically a resistance to TPIV will occur over time, and combing with a checkpoint inhibitor will be particularly more relevant if residual tumor is present. And so the combination with a checkpoint inhibitor, the overall survival results should improve over standard of care. But, it's definitely draining on the stock today.
Here is a study that explains TIL is needed first before adding a mAB checkpoint inhibitor. See the HOWEVER line.
"In immunogenic cancers, such as melanoma, biologic therapies that incorporate PD-1 blocking antibodies (nivolumab or pembrolizumab) have resulted in extended patient survival in randomized controlled trials (34–42). However, as suggested by Tumeh et al., the significant survival benefit in melanoma patients was dependent on a preexisting infiltrating population of cytotoxic T cells (21). A study in GBM patients noted that increased T cell infiltrates at the time of resection were predictive of increased survival (43). Based on our previous work, such T cell infiltration is not consistent across GBM subtypes, with nonmesenchymal subtypes exhibiting a lower endogenous lymphocyte infiltration when compared with mesenchymal GBM (8). Although results of ongoing trials examining GBM treatment with PD-1 mAb alone have not yet been published, we hypothesize that clinical efficacy may be varied and dependent on a preexisting TIL population for PD-1 mAb treatment to work. "
PD-1 blockade enhances the vaccination- induced immune response in glioma
Joseph P. Antonios,1 Horacio Soto,1 Richard G. Everson,1 Joey Orpilla,1 Diana Moughon,1 Namjo Shin,1 Shaina Sedighim,1 William H. Yong,2 Gang Li,3 Timothy F. Cloughesy,4,5,6 Linda M. Liau,1,4,5and Robert M. Prins1,4,5,7
1Department of Neurosurgery, 2Department of Pathology and Laboratory Medicine, 3Department of Biostatistics,?4Brain Research Institute, 5Jonsson Comprehensive Cancer Center (JCCC), 6Department of Neurology, and 7Department of Molecular and Medical Pharmacology, David Ge en School of Medicine at UCLA, UCLA, Los Angeles, California, USA.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951098/pdf/jciinsight-1-87059.pdf
Darth (Eastern Capital) and others used to have 49%, this is probably now a little less after the warrant conversion.
Got this extended versions:
We apologize for sending an outdated press release to you. There was a small hiccup in our email alert software.
With regards to the recent market activity and the trading of TPIV, the company has not issued any news or announcements. We remain entirely focused on the advacement of our T-cell vaccines. Our team is steadfastly devoted to bringing life-changing T-cell vaccines to patients, clinicians and hospitals.
In regards to the Phase I results, we will be publishing soon. Until then we are focused on the advancement of our T-cell vaccines.
I hope this helps. Thank you.
What ever happened to RKmatter
Same here. Could have used the opportunity to inform us on phase 1 publication.
Average volume of 32k shares a day
50% held by big buys
When it swings, it swings violently.
Awesome trading stock
appears original investors are very upset and dumping, new investors want their money back and legal action is being considered by another.
Seems to be a lot of hysteria today, all based on a predetermined agenda to take down a CEO.
If you wanna take him down, then call Darth. He owns just shy of half the company. Not much this board will do.
if insiders are loading, we would see it in SEC forms.
Have not seen any so far.
New options in cancer care
A Florida-based biotechnology company has received fast-track designation from the Food and Drug Administration to develop immunotherapy treatments for ovarian and breast cancers. If the treatment is approved, it could provide a new option for women with bleak diagnoses. Below, Dr. Glynn Wilson, TapImmune's chairman and CEO, discusses the treatment.
How does TapImmune differ from existing treatment options for ovarian and breast cancer?
Ovarian cancer tends to be detected at a later stage of the disease, and the five-year survival rate for ovarian cancer is 45 percent. Current treatment options are surgery, radiation and chemotherapy but the patients are at high risk for recurrence in a relatively short time. There is currently no FDA approved cancer vaccine for ovarian cancer. Triple negative breast cancer, which affects 15 to 20 percent of women who develop breast cancer each year, is a subset of breast cancer for which there is no treatment other than standard surgery and chemotherapy.
TapImmune is developing vaccine immunotherapies designed to create a broad T-cell response including a lasting “memory” T-cell response that may be effective against primary cancer cells and metastases in various types of cancers. Harnessing a person's immune system to treat many types of cancers has long been a dream in the medical field. Today, immune checkpoint inhibitors and other immunomodulatory therapies are already on the market and many more are in development, but none of these work well in breast and ovarian cancer. TapImmune is developing next-generation T-cell vaccines with an initial focus on treating women's cancers, specifically ovarian and breast cancer. We have selected potent antigen combinations that are overexpressed on the majority of cancer cells and can be recognized by the vast majority of patients' immune systems. TapImmune's off-the-shelf immunotherapies are designed to treat a wide patient population across varied therapeutic areas of cancer.
Where does TapImmune stand in the clinical trial process, and when might trials be finished?
TapImmune has enrolled 40 of 80 patients in its randomized Phase 2 clinical study of its novel T-cell vaccine candidate TPIV 200 for treating triple-negative breast cancer. The four-arm study is designed to determine the optimal vaccine dose and regimen to maximize the immune response generated against the vaccine's molecular target, folate receptor-alpha.
Later this year, TapImmune is initiating a full trial with the Mayo Clinic, funded by a grant from the Department of Defense for Triple-Negative Breast Cancer.
TapImmune may have to do further Phase 2 studies before the pivotal Phase 3 studies that would allow licensure of the vaccine(s) over the next several years.
What questions does TapImmune still need to answer with the trials?
Safety of both products was addressed in a preliminary sense in the Phase 1 trials for each product. TapImmune is now looking at the immunogenicity and efficacy. The latter will need to be addressed with a relatively large trial for each product, and the current trials should help TapImmune to better understand how large those future trials might need to be.
1 hour trading and nada volume... bizar
Anavex could (if they wanted) buy Biogen.
One can wait rather a long wait
source please
10 times average volume, something must be up. Either fake liquidity or someone wants cheap shares.
six people out of 32 who have a major improvement in quality of life can not be called anything but conclusive